Khadijeh Mahboobnia

Mrs. Khadijeh Mahboobnia

University of Western Australia, Perth, Western Australia, Australia
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
AFAmirnezam Farboudi
Amirnezam Farboudi
Khadijeh MahboobniaKhadijeh Mahboobnia
Khadijeh Mahboobnia
FCFaraz Chogan
Faraz Chogan
MKMahsa Karimi
Mahsa Karimi
AAAnis Askari
Anis Askari
MIMohammad Irani
Mohammad Irani

1 July 2019 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
MJMania Habibi Jouybari
Mania Habibi Jouybari
SHSeyedehgolshan Hosseini
Seyedehgolshan Hosseini
Khadijeh MahboobniaKhadijeh Mahboobnia
Khadijeh Mahboobnia
LBLily Azadeh Boloursaz
Lily Azadeh Boloursaz
MMMostafa Moradi
Mostafa Moradi
MIMohammad Irani
Mohammad Irani

8 January 2016 in International Journal of Polymeric Materials and Polymeric Biomaterials
Verified
Journal Article
Closed access
LHLayla Hosseini
Layla Hosseini
Khadijeh MahboobniaKhadijeh Mahboobnia
Khadijeh Mahboobnia
MIMohammad Irani
Mohammad Irani
The efficient delivery of daunorubicin loaded poly (lactic acid) (PLA)/multiwalled carbon nanotubes (MWCNT)/Fe3O4 composite nanofibers was investigated. The synthesized nanofibers were characterized using SEM, TEM, and XRD analysis. The proliferation inhibition effect of PLA/MWCNT/Fe3O4 nanofibrous scaffolds on leukemia K562 cell lines was investigated. The effect of nanofiber concentration on the daunorubicin delivery in the absence and presence of external magnetic field was also evaluated. The results indicated that the incorporation of daunorubicin into the prepared nanofibrous scaffold under applied magnetic field could have synergistic cytotoxic effect on leukemia cancer cells. The drug release mechanism followed the non-Fickian transport.

1 March 2019 in International Immunopharmacology
Verified
Journal Article
Closed access
HYHamid Yaghooti
Hamid Yaghooti
NMNarges Mohammadtaghvaei
Narges Mohammadtaghvaei
Khadijeh MahboobniaKhadijeh Mahboobnia
Khadijeh Mahboobnia

Verified
Journal Article
Open access
PDF file
Khadijeh MahboobniaKhadijeh Mahboobnia
Khadijeh Mahboobnia
DBDianne Beveridge
Dianne Beveridge
GYGeorge Cheng Yeoh
George Cheng Yeoh
TKTasnuva D. Kabir
Tasnuva D. Kabir
PLPeter Leedman
Peter Leedman
Hepatocellular carcinoma (HCC) presents a significant global health burden, with alarming statistics revealing its rising incidence and high mortality rates. Despite advances in medical care, HCC treatment remains challenging due to late-stage diagnosis, limited effective therapeutic options, tumor heterogeneity, and drug resistance. MicroRNAs (miRNAs) have attracted substantial attention as key regulators of HCC pathogenesis. These small non-coding RNA molecules play pivotal roles in modulating gene expression, implicated in various cellular processes relevant to cancer development. Understanding the intricate network of miRNA-mediated molecular pathways in HCC is essential for unraveling the complex mechanisms underlying hepatocarcinogenesis and developing novel therapeutic approaches. This manuscript aims to provide a comprehensive review of recent experimental and clinical discoveries regarding the complex role of miRNAs in influencing the key hallmarks of HCC, as well as their promising clinical utility as potential therapeutic targets.

1 January 2014 in Advanced Biomedical Research
Verified
Journal Article
Open access
PDF file
MPMorteza Pourfarzam
Morteza Pourfarzam
Khadijeh MahboobniaKhadijeh Mahboobnia
Khadijeh Mahboobnia
AAAbdolamir Atapour
Abdolamir Atapour
HSHamid Mir Mohammad Sadeghi
Hamid Mir Mohammad Sadeghi
Background: The influence of vitamin D receptor (VDR) gene polymorphisms on the regulation of the parathyroid hormone is important in end-stage renal disease (ESRD) patients. We analyzed rs1544410 (BsmI) and rs731236 (TaqI) polymorphisms of VDR gene in hemodialysis patients to determine their relationship with serum intact parathyroid hormone (iPTH). Materials and Methods : Ninety hemodialysis patients were included in this study. Patients were classified into four groups according to their serum iPTH level. Polymorphisms of VDR gene were surveyed using polymerase chain reaction-restriction fragment length polymorphism method with BsmI and TaqI enzymes in all the patients. Results : Patients age ranged between 30 and 60 years (mean ± SD: 36.0 ± 11.4) and period undergoing hemodialysis 80 ± 71 months. Patients were divided into four groups based on the serum concentration of iPTH. The distribution of VDR gene allelic variation for BsmI and TaqI polymorphisms was different between the four groups of uremic patients. Analysis of data revealed a significant correlation between the TaqI variants and serum iPTH level. There was also a correlation between the BsmI variants and serum iPTH level in that patients with the BB genotype were more likely to have a higher serum iPTH level. However, the latter was not statistically significant. Conclusions: Genotype of the TaqI and BsmI VDR gene polymorphisms is reported in Iranian patients with ESRD. Those with tt or BB genotypes may develop more severe secondary hyperparathyroidism.